Indiplon
Indiplon[edit]

Indiplon is a nonbenzodiazepine hypnotic agent that was developed for the treatment of insomnia. It acts as a positive allosteric modulator of the GABA_A receptor, which is a type of neurotransmitter receptor in the central nervous system.
Mechanism of Action[edit]
Indiplon works by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor. This receptor is a ligand-gated ion channel that, when activated, allows chloride ions to enter the neuron, leading to hyperpolarization and decreased neuronal excitability. By modulating this receptor, Indiplon increases the inhibitory effects of GABA, promoting sedation and sleep.
Pharmacokinetics[edit]
Indiplon is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It is extensively metabolized in the liver by the cytochrome P450 enzyme system, primarily by CYP3A4. The metabolites are excreted in the urine. The half-life of Indiplon is approximately 1 to 2 hours, which makes it suitable for use as a sleep aid with minimal hangover effect the next day.
Clinical Use[edit]
Indiplon was developed to treat insomnia, particularly difficulties with sleep onset. It was designed to have a rapid onset of action and a short duration, making it effective for individuals who have trouble falling asleep but do not necessarily have issues with staying asleep.
Development and Approval[edit]
Indiplon was developed by Neurocrine Biosciences and was submitted for approval to the United States Food and Drug Administration (FDA). However, the FDA issued a non-approval letter, citing concerns about the drug's safety and efficacy profile. As a result, Indiplon was never marketed in the United States.
Side Effects[edit]
Common side effects of Indiplon include drowsiness, dizziness, and headache. Like other hypnotics, it may also cause amnesia, confusion, and impaired coordination. There is also a potential for dependence and withdrawal symptoms with prolonged use.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
Start your transformation today with W8MD weight loss centers.
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian